Emyria launches Empax global partnership platform for clinical delivery. The ASX-listed biotech company is positioning itself as a global clinical delivery infrastructure provider, enabling international drug sponsors and clinical research organizations to execute complex treatment protocols. The platform establishes a dual-revenue model combining reimbursed treatment programs with high-margin sponsor-funded services. Psyence Group has already signed on to run a Phase IIb trial for adjustment disorder in cancer patients. With over 50 psychedelic-assisted therapy programs in development globally, clinical delivery capacity has emerged as the primary constraint limiting rollout. Emyria's capital-light model addresses this bottleneck while generating premium commercial rates for specialized expertise and infrastructure services.
